DK174932B1 - Apolipoprotein B-specifikke monoklonale antistoffer og hybridomaer, som producerer disse antistoffer - Google Patents

Apolipoprotein B-specifikke monoklonale antistoffer og hybridomaer, som producerer disse antistoffer Download PDF

Info

Publication number: DK174932B1
Authority: DK; Denmark
Prior art keywords: receptor; apo; immunoreactant; ldl; apoprotein
Prior art date: 1986-08-06

Application number

DK198704079A

Other languages

Danish (da)

English (en)

Other versions

DK407987D0 (da

DK407987A (da

Inventor

Steven Young

Linda K Curtiss

Joseph L Witztum

Original Assignee

Scripps Clinic Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-06

Filing date

1987-08-05

Publication date

2004-03-01

1987-08-05 Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res

1987-08-05 Publication of DK407987D0 publication Critical patent/DK407987D0/da

1988-02-07 Publication of DK407987A publication Critical patent/DK407987A/da

2004-03-01 Application granted granted Critical

2004-03-01 Publication of DK174932B1 publication Critical patent/DK174932B1/da

Links

210000004408 hybridoma Anatomy 0.000 title claims abstract description 89
102100040202 Apolipoprotein B-100 Human genes 0.000 title description 127
101710095342 Apolipoprotein B Proteins 0.000 title description 3
108010008150 Apolipoprotein B-100 Proteins 0.000 claims abstract description 127
239000000203 mixture Substances 0.000 claims abstract description 73
102000006991 Apolipoprotein B-100 Human genes 0.000 claims abstract 3
102000005962 receptors Human genes 0.000 claims description 257
239000007790 solid phase Substances 0.000 claims description 112
102000006410 Apoproteins Human genes 0.000 claims description 78
108010083590 Apoproteins Proteins 0.000 claims description 78
230000027455 binding Effects 0.000 claims description 70
238000009739 binding Methods 0.000 claims description 70
238000000034 method Methods 0.000 claims description 70
239000007787 solid Substances 0.000 claims description 62
238000002965 ELISA Methods 0.000 claims description 44
210000001124 body fluid Anatomy 0.000 claims description 42
239000010839 body fluid Substances 0.000 claims description 42
239000007791 liquid phase Substances 0.000 claims description 42
239000003153 chemical reaction reagent Substances 0.000 claims description 37
239000011230 binding agent Substances 0.000 claims description 33
230000036046 immunoreaction Effects 0.000 claims description 31
239000011159 matrix material Substances 0.000 claims description 30
238000002156 mixing Methods 0.000 claims description 30
230000002860 competitive effect Effects 0.000 claims description 25
230000009870 specific binding Effects 0.000 claims description 25
238000003556 assay Methods 0.000 claims description 23
102000004190 Enzymes Human genes 0.000 claims description 20
210000002966 serum Anatomy 0.000 claims description 20
108090000790 Enzymes Proteins 0.000 claims description 18
101800001976 Apolipoprotein B-48 Proteins 0.000 claims description 14
102400000352 Apolipoprotein B-48 Human genes 0.000 claims description 14
238000004166 bioassay Methods 0.000 claims description 14
102000016979 Other receptors Human genes 0.000 claims description 13
238000010348 incorporation Methods 0.000 claims description 7
239000002594 sorbent Substances 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 5
108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
238000000926 separation method Methods 0.000 claims description 3
238000002474 experimental method Methods 0.000 claims description 2
230000014759 maintenance of location Effects 0.000 claims description 2
238000002764 solid phase assay Methods 0.000 claims description 2
235000011890 sandwich Nutrition 0.000 claims 8
102000003992 Peroxidases Human genes 0.000 claims 1
108020003175 receptors Proteins 0.000 description 222
102000007330 LDL Lipoproteins Human genes 0.000 description 101
108010007622 LDL Lipoproteins Proteins 0.000 description 101
210000002381 plasma Anatomy 0.000 description 66
239000000523 sample Substances 0.000 description 61
239000000427 antigen Substances 0.000 description 42
108091007433 antigens Proteins 0.000 description 41
102000036639 antigens Human genes 0.000 description 41
102000018616 Apolipoproteins B Human genes 0.000 description 40
108010027006 Apolipoproteins B Proteins 0.000 description 40
102000004895 Lipoproteins Human genes 0.000 description 30
108090001030 Lipoproteins Proteins 0.000 description 30
108090000623 proteins and genes Proteins 0.000 description 29
108091003079 Bovine Serum Albumin Proteins 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 27
238000003127 radioimmunoassay Methods 0.000 description 26
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
239000002953 phosphate buffered saline Substances 0.000 description 25
229940098773 bovine serum albumin Drugs 0.000 description 24
230000000890 antigenic effect Effects 0.000 description 23
108010062497 VLDL Lipoproteins Proteins 0.000 description 20
210000004027 cell Anatomy 0.000 description 20
239000002245 particle Substances 0.000 description 20
241000283973 Oryctolagus cuniculus Species 0.000 description 19
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
206010003445 Ascites Diseases 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
108010001336 Horseradish Peroxidase Proteins 0.000 description 17
108010001831 LDL receptors Proteins 0.000 description 17
102000000853 LDL receptors Human genes 0.000 description 17
210000002950 fibroblast Anatomy 0.000 description 17
239000012530 fluid Substances 0.000 description 16
239000000463 material Substances 0.000 description 16
230000036963 noncompetitive effect Effects 0.000 description 16
239000000499 gel Substances 0.000 description 15
108010004103 Chylomicrons Proteins 0.000 description 14
238000010790 dilution Methods 0.000 description 14
239000012895 dilution Substances 0.000 description 14
239000000872 buffer Substances 0.000 description 13
230000015556 catabolic process Effects 0.000 description 13
238000006731 degradation reaction Methods 0.000 description 13
238000002372 labelling Methods 0.000 description 13
239000000243 solution Substances 0.000 description 13
239000007788 liquid Substances 0.000 description 12
239000002609 medium Substances 0.000 description 12
230000009871 nonspecific binding Effects 0.000 description 12
238000005406 washing Methods 0.000 description 12
108010010234 HDL Lipoproteins Proteins 0.000 description 11
102000015779 HDL Lipoproteins Human genes 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
208000029078 coronary artery disease Diseases 0.000 description 11
239000003446 ligand Substances 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
241000283707 Capra Species 0.000 description 10
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
239000007982 barbital buffer Substances 0.000 description 9
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 9
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
239000000020 Nitrocellulose Substances 0.000 description 8
238000003018 immunoassay Methods 0.000 description 8
238000011534 incubation Methods 0.000 description 8
229920001220 nitrocellulos Polymers 0.000 description 8
229920000936 Agarose Polymers 0.000 description 7
238000008214 LDL Cholesterol Methods 0.000 description 7
229920002684 Sepharose Polymers 0.000 description 7
230000008901 benefit Effects 0.000 description 7
235000012000 cholesterol Nutrition 0.000 description 7
230000000694 effects Effects 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
206010035226 Plasma cell myeloma Diseases 0.000 description 6
229920001213 Polysorbate 20 Polymers 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
238000001155 isoelectric focusing Methods 0.000 description 6
201000000050 myeloid neoplasm Diseases 0.000 description 6
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
239000000047 product Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 5
239000012847 fine chemical Substances 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000004927 fusion Effects 0.000 description 5
239000011521 glass Substances 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
239000004033 plastic Substances 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
239000004800 polyvinyl chloride Substances 0.000 description 5
229920000915 polyvinyl chloride Polymers 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
108010015776 Glucose oxidase Proteins 0.000 description 4
239000004366 Glucose oxidase Substances 0.000 description 4
239000004793 Polystyrene Substances 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
-1 cholesteryl ester Chemical class 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
229940116332 glucose oxidase Drugs 0.000 description 4
235000019420 glucose oxidase Nutrition 0.000 description 4
230000016784 immunoglobulin production Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229920002223 polystyrene Polymers 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
241000894007 species Species 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000012546 transfer Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
102000018655 Apolipoproteins C Human genes 0.000 description 3
108010027070 Apolipoproteins C Proteins 0.000 description 3
102000013918 Apolipoproteins E Human genes 0.000 description 3
108010025628 Apolipoproteins E Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
230000008021 deposition Effects 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
238000005755 formation reaction Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000000444 normolipidemic effect Effects 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
102000013415 peroxidase activity proteins Human genes 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
238000013391 scatchard analysis Methods 0.000 description 3
238000010186 staining Methods 0.000 description 3
238000005199 ultracentrifugation Methods 0.000 description 3
AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 2
101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000005717 Myeloma Proteins Human genes 0.000 description 2
108010045503 Myeloma Proteins Proteins 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
239000002262 Schiff base Substances 0.000 description 2
150000004753 Schiff bases Chemical class 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
229960002319 barbital Drugs 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000007865 diluting Methods 0.000 description 2
239000000975 dye Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
239000011888 foil Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
102000045903 human LPA Human genes 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
230000000951 immunodiffusion Effects 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000008604 lipoprotein metabolism Effects 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
239000013610 patient sample Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102100031417 Elongation factor-like GTPase 1 Human genes 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100027490 H2.0-like homeobox protein Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000866914 Homo sapiens Elongation factor-like GTPase 1 Proteins 0.000 description 1
101001081101 Homo sapiens H2.0-like homeobox protein Proteins 0.000 description 1
101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
102000045576 Lactoperoxidases Human genes 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
101710131583 Trypsin-10 Proteins 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
230000027645 antigenic variation Effects 0.000 description 1
238000002617 apheresis Methods 0.000 description 1
108010058401 apolipoprotein B-15 Proteins 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000006800 cellular catabolic process Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000005352 clarification Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
102000006834 complement receptors Human genes 0.000 description 1
108010047295 complement receptors Proteins 0.000 description 1
239000011365 complex material Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
108010094102 enzymobeads Proteins 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
201000001386 familial hypercholesterolemia Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000007429 general method Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000006353 oxyethylene group Chemical group 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
238000002616 plasmapheresis Methods 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000000344 soap Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK198704079A 1986-08-06 1987-08-05 Apolipoprotein B-specifikke monoklonale antistoffer og hybridomaer, som producerer disse antistoffer DK174932B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89365986A	1986-08-06	1986-08-06
US89365986		1986-08-06

Publications (3)

Publication Number	Publication Date
DK407987D0 DK407987D0 (da)	1987-08-05
DK407987A DK407987A (da)	1988-02-07
DK174932B1 true DK174932B1 (da)	2004-03-01

Family

ID=25401879

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198704079A DK174932B1 (da)	1986-08-06	1987-08-05	Apolipoprotein B-specifikke monoklonale antistoffer og hybridomaer, som producerer disse antistoffer

Country Status (13)

Country	Link
US (2)	US5330910A (fi)
EP (1)	EP0257778B1 (fi)
JP (1)	JP2831352B2 (fi)
AT (1)	ATE120233T1 (fi)
AU (1)	AU7657387A (fi)
CA (1)	CA1338032C (fi)
DE (1)	DE3751182T2 (fi)
DK (1)	DK174932B1 (fi)
ES (1)	ES2070820T3 (fi)
FI (1)	FI92714C (fi)
IE (1)	IE66195B1 (fi)
NO (1)	NO172596C (fi)
PT (1)	PT85490B (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3734015A1 (de) *	1987-10-08	1989-04-20	Behringwerke Ag	Diagnostisches mittel und verfahren zur bestimmung von apolipoprotein b
JPH07104351B2 (ja) *	1988-09-29	1995-11-13	株式会社日本抗体研究所	脂質代謝異常検出用キット
US5183738A (en) *	1988-09-29	1993-02-02	Japan Immuno Research Laboratories Co., Ltd.	Kit for the detection of denatured lipoproteins
KR950008684A (ko) *	1993-09-21	1995-04-19	쇼다 오사무	아포리포프로틴 b로 이루어진 엔도텔린 전환효소
US6107045A (en) *	1994-06-30	2000-08-22	Oklahoma Medical Research Foundation	Antibodies to lipoproteins and apolipoproteins and methods of use thereof
JPH1026621A (ja) *	1996-07-12	1998-01-27	Dai Ichi Pure Chem Co Ltd	イムノアッセイ法
US6506569B1 (en) *	1997-05-30	2003-01-14	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor TR10
US6716410B1 (en)	1999-10-26	2004-04-06	The Regents Of The University Of California	Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
DE60237455D1 (de) *	2001-07-12	2010-10-07	Kyowa Medex Co Ltd	Verfahren zur quantifizierung von denaturiertem lipoprotein
EP1797893B1 (en)	2004-04-15	2010-04-07	Athera Biotechnologies Ab	Antibodies against phosphorylcholine conjugates
US7875182B2 (en) *	2006-11-20	2011-01-25	Cytosorbents, Inc.	Size-selective hemoperfusion polymeric adsorbents
US9182389B2 (en) *	2011-02-22	2015-11-10	Chrome Red Technologies, Llc	Detection of specific antigens in a population of antigens
KR101947758B1 (ko)	2011-08-09	2019-02-14	아테라 바이오테크놀로지스 아베	포스포릴콜린에 대한 신규 항체
WO2013022968A1 (en)	2011-08-09	2013-02-14	Athera Biotechnologies Ab	Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
US10858422B2 (en)	2016-05-31	2020-12-08	Abcentra, Llc	Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10434141B2 (en)	2016-05-31	2019-10-08	Abcentra, Llc	Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4486530A (en) *	1980-08-04	1984-12-04	Hybritech Incorporated	Immunometric assays using monoclonal antibodies
JPS6015559A (ja) *	1983-07-06	1985-01-26	Shiraimatsu Shinyaku Kk	アポリポ蛋白−ｂの酵素免疫測定試薬
DE3338836A1 (de) *	1983-10-26	1985-05-09	Boehringer Mannheim Gmbh	Verfahren zur bestimmung der low density lipoproteine (ldl) und reagenz zu seiner durchfuehrung
JPS60193926A (ja) *	1984-03-15	1985-10-02	Tokyo Daigaku	単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
EP0209543A4 (en) *	1984-12-31	1989-07-11	Internat Genetic Engineering I	FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
US4677057A (en) *	1985-03-11	1987-06-30	Scripps Clinic And Research Foundation	Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
US4828986A (en) *	1986-09-29	1989-05-09	Scripps Clinic And Research Foundation	Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample

1987
- 1987-07-20 EP EP87306413A patent/EP0257778B1/en not_active Expired - Lifetime
- 1987-07-20 DE DE3751182T patent/DE3751182T2/de not_active Expired - Lifetime
- 1987-07-20 AT AT87306413T patent/ATE120233T1/de not_active IP Right Cessation
- 1987-07-20 ES ES87306413T patent/ES2070820T3/es not_active Expired - Lifetime
- 1987-08-04 AU AU76573/87A patent/AU7657387A/en not_active Abandoned
- 1987-08-05 FI FI873410A patent/FI92714C/fi not_active IP Right Cessation
- 1987-08-05 CA CA000543750A patent/CA1338032C/en not_active Expired - Fee Related
- 1987-08-05 DK DK198704079A patent/DK174932B1/da not_active IP Right Cessation
- 1987-08-05 IE IE210487A patent/IE66195B1/en not_active IP Right Cessation
- 1987-08-05 NO NO873271A patent/NO172596C/no not_active IP Right Cessation
- 1987-08-05 PT PT85490A patent/PT85490B/pt unknown
- 1987-08-06 JP JP62197250A patent/JP2831352B2/ja not_active Expired - Lifetime
1989
- 1989-09-27 US US07/415,432 patent/US5330910A/en not_active Expired - Lifetime
1994
- 1994-03-30 US US08/219,963 patent/US5460947A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO172596C (no)	1993-08-11
NO873271L (no)	1988-02-08
IE66195B1 (en)	1995-12-13
JPS63279783A (ja)	1988-11-16
NO873271D0 (no)	1987-08-05
DE3751182T2 (de)	1995-10-26
US5330910A (en)	1994-07-19
FI92714B (fi)	1994-09-15
FI873410A0 (fi)	1987-08-05
NO172596B (no)	1993-05-03
AU7657387A (en)	1988-02-11
PT85490B (pt)	1990-06-29
EP0257778A2 (en)	1988-03-02
US5460947A (en)	1995-10-24
ES2070820T3 (es)	1995-06-16
PT85490A (en)	1987-09-01
DE3751182D1 (de)	1995-04-27
CA1338032C (en)	1996-02-06
EP0257778A3 (en)	1990-03-21
EP0257778B1 (en)	1995-03-22
DK407987D0 (da)	1987-08-05
FI92714C (fi)	1994-12-27
DK407987A (da)	1988-02-07
FI873410L (fi)	1988-02-07
IE872104L (en)	1988-02-06
JP2831352B2 (ja)	1998-12-02
ATE120233T1 (de)	1995-04-15

Publication	Publication Date	Title
DK174932B1 (da)	2004-03-01	Apolipoprotein B-specifikke monoklonale antistoffer og hybridomaer, som producerer disse antistoffer
FI89214B (fi)	1993-05-14	Analysfoerfarande och diagnostiskt system foer ett markerande aemne foer abnorm lipidmetabolism
JP2505218B2 (ja)	1996-06-05	アポリポタンパクａ―１に対して特異性を有するモノクロ―ナル抗体又はそのパラト―プ含有ポリペプチド部分並びにそれを使用する診断装置
US20040106143A1 (en)	2004-06-03	Monoclonal antibody against estrogen stimulated leucine aminopeptidase
Gulizia et al.	1991	Immunoreactivity of anti-streptococcal monoclonal antibodies to human heart valves. Evidence for multiple cross-reactive epitopes
EP0218630A1 (en)	1987-04-22	A diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
EP0433088A1 (en)	1991-06-19	Monoclonal antibodies reactive with a human atheroma associated antigen
EP0741144B1 (en)	2002-07-24	Antiannexin-v monoclonal antibody, process for producing the same, and use therof
JPS62167479A (ja)	1987-07-23	ヒト銅・亜鉛−ス−パ−オキシドジスムタ−ゼのモノクロ−ナル抗体からなるヒト銅・亜鉛−ス−パ−オキシドジスムタ−ゼ測定用試薬およびそれを用いる胃癌の診断方法
KR100222232B1 (ko)	1999-10-01	사람 리포단백질과 반응하는 모노클로날 항체 ferm bp-3755
IE881290L (en)	1988-11-02	Monoclonal antibodies for the selective immunological¹determination of intact procollagen peptide (Type III) and¹procollagen (Type III) in body fluids
Curtiss et al.	1996	Selection of monoclonal antibodies for linear epitopes of an apolipoprotein yields antibodies with comparable affinity for lipid-free and lipid-associated apolipoprotein
JPH0431762A (ja)	1992-02-03	心筋梗塞の判定方法
Milthorp et al.	1986	Immunological Characterization of Apolipoprotein AI from Normal Human Plasma: Mapping of Antigenic Determinants
Li	1992	Production, characterization, and use of monoclonal antibodies directed against bovine platelet thrombospondin
Girard et al.	1996	A novel anti-microfilament antibody, anti-135 kD, is associated with Raynaud's disease, undifferentiated connective tissue disease and systemic autoimmune diseases

Legal Events

Date	Code	Title	Description
2007-08-20	PUP	Patent expired